CA2974369A1 - Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing - Google Patents

Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing Download PDF

Info

Publication number
CA2974369A1
CA2974369A1 CA2974369A CA2974369A CA2974369A1 CA 2974369 A1 CA2974369 A1 CA 2974369A1 CA 2974369 A CA2974369 A CA 2974369A CA 2974369 A CA2974369 A CA 2974369A CA 2974369 A1 CA2974369 A1 CA 2974369A1
Authority
CA
Canada
Prior art keywords
mice
net
pad4
inhibitor
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2974369A
Other languages
English (en)
French (fr)
Inventor
Denisa D. Wagner
Siu Ling WONG
Luise ERPENBECK
Kimberly Lindsay MARTINOD
Jorn Thilo Witsch
Alexander SAVCHENKO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of CA2974369A1 publication Critical patent/CA2974369A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2974369A 2015-01-20 2016-01-19 Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing Abandoned CA2974369A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562105342P 2015-01-20 2015-01-20
US62/105,342 2015-01-20
PCT/US2016/013847 WO2016118476A1 (en) 2015-01-20 2016-01-19 Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing

Publications (1)

Publication Number Publication Date
CA2974369A1 true CA2974369A1 (en) 2016-07-28

Family

ID=56417634

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2974369A Abandoned CA2974369A1 (en) 2015-01-20 2016-01-19 Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing

Country Status (5)

Country Link
US (3) US11400139B2 (enExample)
EP (2) EP3247386A4 (enExample)
JP (1) JP2018503685A (enExample)
CA (1) CA2974369A1 (enExample)
WO (1) WO2016118476A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351263A1 (en) * 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
IL317968A (en) 2017-08-18 2025-02-01 Neutrolis Inc Engineered deoxyribonuclease enzymes and their use in medicine
EP3761971A4 (en) * 2018-03-09 2021-11-10 The University of Memphis Research Foundation FLAMMATION INHIBITION COMPOSITIONS AND METHODS
EP3813555A4 (en) * 2018-06-29 2022-03-30 Tets, Viktor, Veniaminovich COMPOSITIONS FOR MODULATION OF INTESTINAL FLORA
IL291111B2 (en) * 2019-09-06 2024-01-01 Consejo Nacional De Investigaciones Cientificas Y Tecn Pharmaceutical composition for topical wound treatment
GB202012326D0 (en) * 2020-08-07 2020-09-23 Citryll B V Diagnostic
CN113358872B (zh) * 2021-06-03 2022-10-21 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于评估肿瘤免疫治疗疗效的标志物组及系统

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US6919320B1 (en) * 1987-10-28 2005-07-19 Wellstat Therapeutics Corporation Pharmaceutical compositions containing deoxyribonucleosides for wound healing
GB8824593D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
DE68928934T2 (de) 1988-12-23 1999-08-05 Genentech, Inc., South San Francisco, Calif. Verfahren zur herstellung von menschlicher dnase
DE3903672C1 (enExample) 1989-02-08 1990-02-01 Lohmann Gmbh & Co Kg
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5540935A (en) 1993-12-06 1996-07-30 Nof Corporation Reactive vesicle and functional substance-fixed vesicle
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
US5539878A (en) 1995-06-16 1996-07-23 Elonex Technologies, Inc. Parallel testing of CPU cache and instruction units
US5858397A (en) 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
ATE321882T1 (de) 1997-07-01 2006-04-15 Isis Pharmaceuticals Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
EP1156812A4 (en) 1999-02-23 2004-09-29 Isis Pharmaceuticals Inc MULTIPARTICULAR FORMULATION
IT1318539B1 (it) 2000-05-26 2003-08-27 Italfarmaco Spa Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente
WO2003015698A2 (en) 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
CA2555199A1 (en) 2004-02-04 2005-08-18 Yokohama City University Peptidylarginine deiminase 4 inhibitor
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
WO2007056389A2 (en) 2005-11-07 2007-05-18 University Of South Carolina Synthesis and use of novel inhibitors and inactivators of protein arginine deiminases
WO2009121183A1 (en) 2008-04-03 2009-10-08 Kane Biotech Inc. Dispersinbtm, 5-fluorouracil, deoxyribonuclease i and proteinase k-based antibiofilm compositions and uses thereof
KR20110063731A (ko) 2008-06-16 2011-06-14 치라릭스 비.브이. 펩티딜아르기닌 디이미나아제(ｐａｄ) 억제제
US9642822B2 (en) * 2011-05-27 2017-05-09 Children's Medical Center Corporation Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
EP2775304A1 (en) * 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
CN105101989B (zh) * 2013-04-09 2019-10-18 加贺谷伸治 白细胞的细胞外诱捕网形成的抑制剂
GB201309180D0 (en) 2013-05-21 2013-07-03 Ucl Business Plc Compounds and Their Uses
WO2014206856A1 (en) * 2013-06-24 2014-12-31 Dentsply Ih Ab Medical device comprising collagen-vi

Also Published As

Publication number Publication date
EP3797789B1 (en) 2024-08-21
US20180271953A1 (en) 2018-09-27
JP2018503685A (ja) 2018-02-08
US20230190886A1 (en) 2023-06-22
EP3247386A1 (en) 2017-11-29
US11400139B2 (en) 2022-08-02
EP3247386A4 (en) 2018-10-03
EP3797789A1 (en) 2021-03-31
WO2016118476A1 (en) 2016-07-28
US20250242000A1 (en) 2025-07-31

Similar Documents

Publication Publication Date Title
US20250242000A1 (en) Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing
US11819540B2 (en) Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
Weiner et al. The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin
Bellocchio et al. TLRs govern neutrophil activity in aspergillosis
RU2636820C2 (ru) Способы и применения ингибиторов пропротеиновой конвертазы субтилизин кексин типа 9(pcsk9)
US9533002B2 (en) Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-β
CN104602682A (zh) 新方法
Han et al. p-Cresyl sulfate promotes the formation of atherosclerotic lesions and induces plaque instability by targeting vascular smooth muscle cells
WO2014180229A1 (zh) 仿生重组高密度脂蛋白在制备预防和治疗阿尔茨海默病药物中的应用
US20230277559A1 (en) Compositions and Methods for the Treatment of Inflammation in Urological Pathology
CN109890364A (zh) 糖尿病肾病的预防和治疗
Yang et al. Liver kinase B1/AMP-activated protein kinase pathway activation attenuated the progression of endotoxemia in the diabetic mice
Ueki et al. D-ribose ameliorates cisplatin-induced nephrotoxicity by inhibiting renal inflammation in mice
Bostancı et al. Prevalence of periodontal disease in patients with Familial Mediterranean Fever: a cohort study from central Turkey
US20240279657A1 (en) Compositions and methods for the prevention and treatment of hemoglobinopathies
EP4611728A1 (en) Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases
KR20250144994A (ko) Zln-005 및 관련 화합물의 용도
Jawale et al. Metabolic ‘De-Programming’of Neutrophils Protects Against Fatal Bloodstream Fungal Infections in Kidney Disease
JP2025540914A (ja) Ｎｌｒｐ１２およびｎｌｒｃ５モジュレーター、ならびにそれらを使用して疾患を調節する方法
JP2017200890A (ja) 生物活性を有するタンパク質を含む糖尿病または糖尿病合併症に用いる治療薬
WO2024238337A1 (en) Dual-domain peptide for depleting hmgb1 from the circulation via liver hspg system
TW201249436A (en) Use of epigallocatechin-3-gallate for immune regulation
Sormendi Gómez The Oxygen Sensor Hif-Prolyl Hydroxylase-2 (Phd2) Is a prominent regulator of the Neutrophil Inflammatory Response

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210105

EEER Examination request

Effective date: 20210105

FZDE Discontinued

Effective date: 20230321

FZDE Discontinued

Effective date: 20230321